Unraveling the mysteries of serum albuminâ€”more than just a serum protein by Angelica M. Merlot et al.
MINI REVIEW ARTICLE
published: 12 August 2014
doi: 10.3389/fphys.2014.00299
Unraveling the mysteries of serum albumin—more than
just a serum protein
Angelica M. Merlot*, Danuta S. Kalinowski and Des R. Richardson*
Molecular Pharmacology and Pathology Program, Department of Pathology, Faculty of Medicine, Bosch Institute, The University of Sydney, Sydney,
NSW, Australia
Edited by:
Ovidiu Constantin Baltatu, University
Camilo Castelo Branco, Brazil
Reviewed by:
Bruno Vogt, Inselspital - University
of Berne, Switzerland
Ovidiu Constantin Baltatu, University
Camilo Castelo Branco, Brazil
*Correspondence:
Angelica M. Merlot and
Des R. Richardson, Molecular
Pharmacology and Pathology
Program, Department of Pathology,
Faculty of Medicine, Bosch Institute,
The University of Sydney, Blackburn
Building D06, Sydney, NSW 2006,
Australia
e-mail: amer7408@
uni.sydney.edu.au;
d.richardson@med.usyd.edu.au
Serum albumin is a multi-functional protein that is able to bind and transport numerous
endogenous and exogenous compounds. The development of albumin drug carriers is
gaining increasing importance in the targeted delivery of cancer therapy, particularly as
a result of the market approval of the paclitaxel-loaded albumin nanoparticle, Abraxane®.
Considering this, there is renewed interest in isolating and characterizing albumin-binding
proteins or receptors on the plasma membrane that are responsible for albumin uptake.
Initially, the cellular uptake and intracellular localization of albumin was unknown due to
the large confinement of the protein within the vascular and interstitial compartment of
the body. Studies have since assessed the intracellular localization of albumin in order
to understand the mechanisms and pathways responsible for its uptake, distribution and
catabolism in multiple tissues, and this is reviewed herein.
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SERUM ALBUMIN
STRUCTURE
Serum albumin is the most abundant protein in the blood plasma
of all vertebrates with the concentration in human serum being
35–50mg/mL (Peters, 1996). Human serum albumin (HSA) has
a molecular mass of 66,348 Da and is composed of three homolo-
gous domains, numbered I, II, and III (Figure 1) (He and Carter,
1992; Peters, 1996; Sugio et al., 1999). Each domain is grouped
into subdomains A and B that possess common structural motifs.
The two principal regions responsible for ligand-binding to HSA
are known as Sudlow’s Site I and II, located in subdomain IIA
and IIIA (Figure 1), respectively (Sudlow et al., 1976; Peters,
1996). Albumin is coded by a single gene, which is expressed
in a co-dominant manner with both alleles being transcribed
and translated (Hawkins and Dugaiczyk, 1982; Peters, 1996). The
human albumin gene is located on the long arm of chromosome
4 at position q13.3.
FUNCTION
Albumin is primarily synthesized by the liver with the human liver
producing ∼13.9 g of HSA per day (Peters, 1996). HSA has an
approximate half-life of 19 days and is degradedmore effectively if
it is denatured or structurally altered (Peters, 1996). Albumin has
a variety of important functions and is responsible for 80% of the
colloidal osmotic pressure of blood (Peters, 1996). Significantly,
albumin is able to bind various endogenous molecules, includ-
ing long-chain fatty acids, steroids, L-tryptophan, etc. (Kragh-
Hansen, 1981; Peters, 1996; Evans, 2002). Moreover, albumin is
also involved in transporting ions in the circulation, including
copper, zinc, calcium, etc. (Peters, 1996).
Additionally, this vital protein is able to bind exogenous com-
pounds and drugs, such as warfarin, ibuprofen, chlorpromazine
and naproxen, with the affinity of their binding significantly
affecting their activity and half-life (Kragh-Hansen, 1981; Peters,
1996; Evans, 2002). Furthermore, albumin also acts as a toxic
waste carrier, binding bilirubin, the product of heme breakdown,
to deliver it to the liver for hepatic excretion (Peters, 1996).
Interestingly, albumin is also believed to act as an anti-oxidant
on account of its ability to: (1) protect bound substances from
peroxidative damage (e.g., fatty acids and lipoproteins); and (2)
bind free copper, limiting its redox activity and the production
of free radicals (Peters, 1996; Evans, 2002). Lastly, albumin is a
source of thiols that are avid reactive oxygen and nitrogen species
scavengers (Peters, 1996; Evans, 2002).
DISTRIBUTION
Interestingly, albumin is predominately present in the extravas-
cular space (∼242 g) rather than the intravascular space (∼118 g)
(Peters, 1996; Evans, 2002). In fact, the protein is prevalent in
extracellular locations such as skin, gut, muscle, other fluids (i.e.,
cerebrospinal, pleural, etc.) and secretions (e.g., sweat, tears and
milk) (Peters, 1996). However, very low concentrations of albu-
min are present intracellularly (Peters, 1996). Albumin returns
from the extravascular space to the circulation via the lymphatic
system, making ∼28 “trips” in and out of the lymphatic system
during its lifetime (Peters, 1996; Evans, 2002).
Upon secretion from hepatocytes, albumin enters the circu-
lation and translocates to the extracellular space through the
pores of sinusoidal or fenestrated endothelium in certain organs,
such as the liver, pancreas, small intestine and bone marrow
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FIGURE 1 | Structure of human serum albumin consisting of three
domains, each grouped into subdomains A and B (Subdomain Ia,
yellow; Ib, green; IIa, red; IIb, magenta; IIIa, blue; and IIIb, cyan). Sugio
et al. (1999) by permission of Oxford University Press.
(Peters, 1996). However, in organs where a continuous endothe-
lium predominates, it is now believed that albumin can traverse
the endothelium via active transcytotic mechanisms, includ-
ing receptor-mediated mechanisms (e.g., albondin; see Section
entitled “Cellular Albumin-Binding Proteins”).
ACCUMULATION OF ALBUMIN IN THE TUMOR
INTERSTITIUM
Solid tumors commonly possess an immature, highly perme-
able vasculature that is acted upon by vascular permeability-
enhancing factors (e.g., nitric oxide) (Carmeliet and Jain, 2000;
Maeda et al., 2000; Greish, 2007; van der Veldt et al., 2008).
However, despite this there is generally insufficient lymphatic
drainage (Carmeliet and Jain, 2000; Maeda et al., 2000; Greish,
2007). This subsequently results in an accumulation of macro-
molecules (>40 kDa) within the tumor interstitium, and this
is known as the enhanced permeation and retention effect
(Figure 2) (Maeda et al., 2000; Greish, 2007). Of interest,
Matsumura and Maeda (1986) demonstrated that an intra-
venously injected Evans blue-albumin complex accumulated in
sarcoma 180 tumors of ddY mice. The retention of albumin
in tumors has since been observed in various experimental
solid tumors (e.g., sarcoma, ovarian carcinoma, Novikof hep-
atoma, etc.) using radiolabeled- or dye-complexed serum albu-
min (Peterson and Appelgren, 1973; Sinn et al., 1990; Andersson
et al., 1991; Schilling et al., 1992; Stehle et al., 1997; Wunder et al.,
1997).
Additionally, a number of studies have proposed that tumors
are a site of albumin catabolism (Hradec, 1958; Andersson et al.,
1991; Schilling et al., 1992; Stehle et al., 1997). For instance, in
FIGURE 2 | Schematic representation of (A) normal and (B) tumor vascu-
lature. Normal tissue is composed of mature, organized blood vessels, while
tumor tissue consists of immature, leaky and tortuous vessels. The altered
organization of tumor vasculature and disorganized lymphatic network results
in vascular leakage and the accumulation ofmacromolecules (>40 kDa)within
the interstitium and is known as the enhanced permeation and retention
(EPR) effect. Adapted by permission from Macmillan Publishers Ltd: Nature
Medicine (Jain, 2001), copyright (2001).
a mouse sarcoma model (C57/RL6J) injected with 3H-raffinose-
labeled albumin, at least 2–3-fold greater levels of 3H were
observed in the lysosomes of tumors when compared with lyso-
somes of normal tissue (Andersson et al., 1991). Furthermore
studies have demonstrated that albumin has a shorter half-life
and a higher turnover in tumor-bearing mice, despite a com-
pensatory increase in hepatic albumin synthesis, compared to
non-tumor-bearing mice (Hradec, 1958). Hence, it has been
suggested that tumors utilize albumin as a source of energy,
by breaking down albumin into its component amino acids in
lysosomes that are subsequently used by cancer cells for their
accelerated growth (Stehle et al., 1997). Moreover, studies have
suggested that the hypoalbuminiemia evident in cancer patients is
a result of albumin catabolism by the tumor (Stehle et al., 1997).
Nevertheless, some of these earlier studies suffer from sev-
eral experimental limitations. For instance, it is difficult to obtain
pure lysosomal fractions and, thus, it is necessary to reproduce
these studies and test the purity of fractions using well established
membrane and organelle markers (Graham, 2002; Yamagishi
et al., 2013). Additionally, several other in vivo factors may affect
albumin degradation and catabolism (e.g., levels of corticos-
teroids) (Peters, 1996). Therefore, a clear-cut relationship has not
been established and additional in vivo studies are necessary to
support the intracellular distribution and catabolism of albumin
by tumors.
More recently, Commisso et al. observed that cancer cells
harboring endogenous oncogenic Ras mutations have increased
levels of macropinocytosis in vitro and in vivo (Commisso et al.,
2013). Moreover, it was demonstrated that FITC-labeled albumin
was internalized through macropinocytosis and subsequently
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resulted in increased levels of glutamate and α-ketoglutarate
in oncogenic Ras-transformed cells (Commisso et al., 2013).
Interestingly, the decrease in proliferation of oncogenic Ras-
expressing cells after glutamine deprivation was shown to be
rescued by extracellular albumin supplementation (Commisso
et al., 2013). These findings suggest that macropinocytosis of
albumin provides nutrients to sustain cancer cell proliferation
(Commisso et al., 2013).
CELLULAR ALBUMIN-BINDING PROTEINS
Considering the importance of albumin, a number of puta-
tive albumin-binding proteins and receptors have been identified
in various tissues and cell lines (Table 1), including kid-
ney (Zhai et al., 2000; Amsellem et al., 2010), endothelium
(Schnitzer and Bravo, 1993), fibroblasts (Porter et al., 1995),
and tumor-cell surfaces (Fritzsche et al., 2004). Specifically, seven
membrane-associated albumin-binding proteins have been dis-
covered, namely: albondin/glycoprotein 60 (gp60) (Schnitzer
et al., 1988), glycoprotein 18 (gp18) (Ghinea et al., 1988), glyco-
protein 30 (gp30) (Ghinea et al., 1988), the neonatal Fc receptor
(FcRn) (Roopenian and Akilesh, 2007), heterogeneous nuclear
ribonucleoproteins (hnRNPs) (Fritzsche et al., 2004), calreticulin
(Fritzsche et al., 2004), cubilin (Zhai et al., 2000; Amsellem et al.,
2010), and megalin (Zhai et al., 2000; Amsellem et al., 2010).
Moreover, a secreted albumin-binding protein known as secreted
protein, acidic and rich in cysteine (SPARC) has been identified
(Schnitzer and Oh, 1992). Considering their importance in albu-
min uptake by cells, each of these proteins are described in detail
below.
ALBONDIN/gp60
Albondin (gp60) is a 60 kDa glycoprotein that acts as an albu-
min receptor that is widely distributed, but is selectively expressed
on the plasma membrane of continuous endothelium (except
for the brain), where it operates to increase capillary permeabil-
ity (Ghinea et al., 1988, 1989; Schnitzer et al., 1988; Schnitzer,
1992; Schnitzer and Oh, 1994; Tiruppathi et al., 1996). Albondin
not only specifically binds native albumin, but also facilitates
its internalization and subsequent transcytosis (Milici et al.,
1987; Schnitzer, 1992; Schnitzer and Oh, 1994; Tiruppathi et al.,
1996).
It has been proposed that ∼50% of albumin leaves the cap-
illary lumen via albondin, with the remainder traversing this
barrier through intercellular junctions and/or fluid-phase mech-
anisms (Schnitzer, 1993; Schnitzer and Oh, 1994). Moreover,
it has been demonstrated that the internalization of albondin
occurs through a caveolin-dependent endocytotic process that
results in transcytosis and does not appear to enter the degrada-
tive endosome-lysosome system (Schnitzer, 1993; Schnitzer and
Bravo, 1993; Schnitzer et al., 1995; Tiruppathi et al., 1997; Iancu
et al., 2011).
gp18 AND gp30
Both gp18 and gp30 avidly bind conformationally-modified
albumin (i.e., gold-labeled albumin, formaldehyde- or maleic-
anhydride-treated albumin) and do not preferentially interact
with native albumin, similarly to other known scavenger recep-
tors (Ghinea et al., 1989; Schnitzer and Oh, 1992, 1994; Schnitzer
et al., 1992; Schnitzer and Bravo, 1993). Unlike albondin, gp18
and gp30 are found on a variety of cells, such as macrophages
and fibroblasts, and a range of endothelia (Schnitzer et al., 1992).
Moreover, gp18 has been observed to be expressed in human
MDA-MB-453 breast cancer cells (Wang et al., 1994). These
scavenger receptors bind and direct modified albumins for degra-
dation, perhaps as part of protein catabolism or as a protective
pathway to remove altered, old, damaged or potentially dele-
terious albumins (Schnitzer, 1993; Schnitzer and Bravo, 1993).
Albumin may be modified through oxidation, non-enzymatic
glycation, maleylation, etc. as a result of normal aging or as
a protective or pathological response (Schnitzer, 1993; Peters,
1996). Denatured or modified albumin is degraded faster and
more efficiently than native albumin, suggesting that these
alterations select albumin molecules for degradation (Peters,
1996).
SPARC
SPARC is also known as osteonectin and BM-40 and is secreted by
several cell types (Brekken and Sage, 2001). Interestingly, SPARC
Table 1 | Localization of albumin-binding proteins and receptors.
Protein/Receptor Tissue Substrate
Albondin/gp60 Continuous endothelium Native albumin
gp18 Endothelium, macrophages, fibroblasts and MDA-MB-453 breast cancer cell surfaces Modified-albumin
gp30 Endothelium, macrophages, fibroblasts and MDA-MB-453 breast cancer cell surfaces Modified-albumin
SPARC Endothelial cells, vascular smooth muscle cells, skeletal muscle, fibroblasts, testicular, ovarian,
pancreatic and a range of tumor cells
Native albumin
hnRNPs Human tumor cell lines: CEM T-cell leukemia cells, MCF-7 breast cancer cells and MV3 melanoma cells Native albumin
Calreticulin Human tumor cell lines: CEM T-cell leukemia cells, MCF-7 breast cancer cells and MV3 melanoma cells Native albumin
FcRn Endothelium, antigen-presenting cells, gut, kidneys, lungs and the blood-brain-barrier (central nervous
system endothelium and choroid plexus)
Native albumin
Cubilin Kidney proximal tubule cells, absorptive intestinal cells, placenta, and visceral yolk-sac cells Native albumin and prob-
ably modified-albumin
Megalin Kidney proximal tubule cells, absorptive intestinal cells, placenta, visceral yolk-sac cells, choroid
plexus, thyrocytes, ciliary epithelium, lungs, parathyroid, endometrium, oviduct, inner ear, and
epididymal epithelial cells
Native albumin and prob-
ably modified-albumin
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has been found to be highly expressed in malignant cells and stro-
mal cells associated with neoplasia (Porter et al., 1995; Podhajcer
et al., 2008). SPARC possesses albumin-binding properties and
specifically interacts with native albumin in a similar way to
albondin, but differing from 18 to gp30 that bind conformation-
ally altered albumin (Schnitzer and Oh, 1992). Specifically, anti-
SPARC antibodies also recognize albondin, but not 18 or gp30,
suggesting that SPARC and albondin share a native albumin-
binding domain (Schnitzer and Oh, 1992). However, there is no
evidence that SPARC mediates albumin uptake into tumors. It
has been postulated that the ability of SPARC to bind albumin in
the tumor interstitium enhances the accumulation of albumin-
bound drugs within the tumor space (Desai et al., 2008, 2009).
Moreover, a preliminary clinical trial demonstrated that SPARC
expression correlated with the response to paclitaxel-loaded albu-
min nanoparticle (nab-paclitaxel or Abraxane®) treatment, with
SPARC-positive patients having a better clinical outcome (Desai
et al., 2009). However, conflicting data in a KPfC mouse model
has challenged this hypothesis, as SPARC deficiency did not alter
the intra-tumoral concentrations of Abraxane® (Neesse et al.,
2014). Consequently, further studies are necessary to validate
this hypothesis, including larger clinical trials involving a greater
number of patients. Currently, a phase III study (NCT00785291),
by the National Cancer Institute, is evaluating whether SPARC
expression in serum predicts patient response to Abraxane®, and
this may further our understanding of the role of SPARC in
albumin accumulation by tumors.
hnRNPs AND CALRETICULIN
Five different albumin-binding proteins have been identified from
plasma membranes of human cancer cells lines (i.e., CCRF-CEM
T-cell leukemia, MV3 melanoma and MCF7 breast carcinoma)
(Fritzsche et al., 2004). Four of these proteins were identified as
members of the hnRNP family, including hnRNP A2/B1, hnRNP
C1, hnRNP A1 and hnRNP A3, and the fifth protein was found
to be calreticulin (Fritzsche et al., 2004). Calreticulin was first
described as an endoplasmic reticulum chaperone and calcium
signaling protein, but has since been shown to be involved in
several cellular functions, including cell adhesion, modulation
of platelet-collagen interactions (wound healing) and apoptosis
(Mendlovic and Conconi, 2010). The functions of the hnRNP
family are not well characterized. However, most members of
the hnRNP family have been described as nuclear RNA-binding
proteins involved in pre-mRNA processing, such as RNA splic-
ing, export and stability (Chaudhury et al., 2010). Interestingly,
hnRNPs have been proposed to play a role in carcinogenesis
where their over-expression acts as biomarkers for the early detec-
tion of tumors (Han et al., 2013). The significance of these
findings is currently unclear and it remains to be determined
whether these proteins are involved in albumin-mediated uptake.
FcRn
FcRn is expressed in multiple cell-types and tissues, includ-
ing antigen-presenting cells, vascular endothelium, gut, lungs,
kidneys and the blood-brain barrier (BBB) (i.e., endothelium and
choroid plexus) (Roopenian and Akilesh, 2007). This receptor
protects albumin and IgG, from degradation by binding both
proteins with high affinity only at a low pH (pH < 6.5) in
acidic endosomes, preventing their degradation via the lysosomal
pathway and returning them to the extracellular space (pH 7.4)
(Chaudhury et al., 2003; Ober et al., 2004; Anderson et al., 2006;
Andersen et al., 2012). This consequently extends the half-life of
serum albumin (Chaudhury et al., 2003; Anderson et al., 2006;
Sarav et al., 2009). The role of this receptor in albumin uptake by
tumors remains unclear.
CUBILIN AND MEGALIN
Cubilin is a multi-ligand receptor that is most recognized for its
involvement in the intestinal uptake of the intrinsic factor vitamin
B12 complex (Seetharam et al., 1997). Moreover, cubilin has been
shown to be involved in the endocytosis and transcellular trans-
port of numerous ligands, including albumin (Birn et al., 2000).
Cubilin is localized to absorptive intestinal cells, placenta, visceral
yolk-sac cells and proximal tubules of kidneys (Christensen and
Birn, 2002). Megalin is a large trans-membrane protein that has
also been shown to bind albumin (Cui et al., 1996). This protein is
more widely expressed than cubilin, being present in the choroid
plexus, kidney proximal tubule cells, thyrocytes, etc. (Table 1)
(Christensen and Birn, 2002).
Interestingly, megalin binds to cubilin with high affinity and
it has been suggested that megalin contributes to the internal-
ization of cubilin-ligand complexes as a co-receptor (Moestrup
et al., 1998; Christensen and Birn, 2002). Moreover, cubilin also
binds amnionless, a protein that is necessary for the expres-
sion of cubilin on the cell membrane (Amsellem et al., 2010).
Cubilin, in conjunction with megalin, has an essential role
in the uptake of albumin (i.e., reabsorption) by the proximal
tubules of the kidneys (Zhai et al., 2000; Amsellem et al., 2010).
Cubilin- and/or megalin-deficiency in mice and dogs was shown
to cause a decrease in the uptake of albumin in the proximal
tubule resulting in albuminuria (Birn et al., 2000; Amsellem
et al., 2010). Additionally, patients with Imerslund-Gräsbeck syn-
drome, caused by a mutation in the cubilin gene, in general suffer
from proteinurea, demonstrating the importance of cubilin in
protein renal reabsorption (Grasbeck, 2006).
ALBUMIN AS A DRUG CARRIER IN ONCOLOGY
Considering the enhanced permeation and retention effect and
the accumulation of albumin in the tumor interstitium, the devel-
opment of albumin as a drug carrier is increasingly important to
consider in terms of the targeted delivery of cancer therapy (Kratz,
2008, 2010). It has also been proposed that albumin carriers take
advantage of the presence of albondin on the endothelium and
SPARC in the tumor interstitium to increase the accumulation
of drugs in the tumor space (Desai et al., 2009; Kratz, 2010).
Various drug delivery systems with albumin have been devel-
oped including albumin nanoparticles, drug albumin conjugates,
albumin-binding drug derivatives and prodrugs (for reviews see
Kratz, 2008, 2010).
The development and market approval of the paclitaxel-
loaded albumin nanoparticle, nab-paclitaxel or Abraxane®, was a
major breakthrough in the field of albumin carrier development.
Abraxane® was initially approved for clinical use in the United
States in 2005 (Kudlowitz and Muggia, 2014). This albumin
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nanoparticle is indicated for the treatment of metastatic breast
cancer, after failure of combination chemotherapy (Kudlowitz
and Muggia, 2014). More recently, Abraxane® has also been
described for the first-line treatment of patients with metastatic
adenocarcinoma of the pancreas, in combination with gemc-
itabine, and patients with locally advanced or metastatic non-
small cell lung carcinoma, in combination with carboplatin
(Kudlowitz and Muggia, 2014). Abraxane® has a greater thera-
peutic index than paclitaxel alone, being administered at higher
doses with less toxicity and more efficacy than traditional pacli-
taxel therapy (Gradishar et al., 2005; Socinski et al., 2012;
Iwamoto, 2013). Abraxane® is currently still being further eval-
uated in clinical trials for other tumors, such as cancer of the
bladder (NCT00583349) andmultiple myeloma (NCT02075021).
Moreover, albumin-binding as a general strategy for improv-
ing the pharmacokinetics of drugs is also being assessed.
Traditionally, the binding of a drug to albumin is believed to
reduce the level of free drug available to exert its therapeutic
activity (Lancon et al., 2004; Vuignier et al., 2010). However, stud-
ies have also demonstrated mechanisms by which albumin acts
to effectively improve therapeutic use or reduce rapid clearance
(Dennis et al., 2002; Merlot and Richardson, 2014). For instance,
the experimental anti-cancer thiosemicarbazone, namely di-
2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT)
(Merlot et al., 2013a), has been shown to be internalized by
cancer cells via a putative carrier/receptor (Merlot et al., 2013b;
Merlot and Richardson, 2014). Interestingly, the uptake, toxic-
ity and apoptotic activity of Dp44mT is greatly enhanced in the
presence of HSA (Merlot and Richardson, 2014). Considering
Dp44mT targets lysosomes to induce apoptosis (Lovejoy et al.,
2011), and that HSA potentially undergoes lysosomal catabolism
in tumors (Andersson et al., 1991; Stehle et al., 1997), it can be
hypothesized that HSA facilitates Dp44mT delivery to the lyso-
somes, enhancing its anti-cancer activity (Merlot and Richardson,
2014). Although studies are yet to identify the exact mechanism of
the HSA-stimulated uptake process, albumin-binding may pro-
vide an advantage when generating tumor targeting agents and
this requires further intense investigation.
CONCLUSION
Albumin is a versatile and captivating protein. In view of the large
confinement of albumin within the vascular and interstitial space,
the intracellular distribution of albumin has remained poorly
characterized for many years. It may be possible that albumin,
under specific conditions or during cellular stress, is taken up by
normal cells and tumor cells at low and high levels, respectively,
due to their metabolic rate. The exact role of some incompletely
characterized albumin-binding proteins (i.e., hnRNPs and calreti-
culin) in mediating albumin uptake remains to be determined.
However, the search and characterization of albumin-binding
proteins, particularly in cancer cells, is of considerable interest in
light of the development of albumin as an effective drug carrier to
target tumors.
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